Optimizerx Corp (OPRX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. OptimizeRx Corporation is a digital healthcare technology company connecting healthcare professionals and patients via an omnichannel network. The company operates as a single reporting segment, focusing on life sciences marketing solutions. As of July 30, 2026, there were 18,835,951 common shares outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Net Revenue | $20.5 million | $40.3 million |
| Net Income (Loss) | $(0.7) million | $(1.2) million |
| Operating Income (Loss) | $(0.1) million | $0.3 million |
| Operating Margin | -0.4% | 0.8% |
| Cash and Cash Equivalents | $24.1 million (as of June 30, 2026) | N/A |
| Working Capital | $44.4 million | N/A |
| Total Debt (Current + Long-term) | $19.0 million | N/A |
| EPS (Basic & Diluted) | $(0.04) | $(0.06) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 30% year-over-year for the quarter and 21% for the six-month period. This was primarily driven by an $8.4 million decline in a low-margin managed service program and the loss of a customer representing ~10% of 2025 revenue.
- Expense Reduction: Total expenses decreased 21% for the quarter and 20% for the six-month period. Cost of revenues dropped significantly (from 36% to 23% of revenue for the quarter) due to the exit of low-margin contracts.
- Profitability Shift: The company reported a net loss of $0.7 million for the quarter, compared to net income of $1.5 million in the same period in 2025. Operating income turned negative for the quarter but remained slightly positive for the six-month period.
- Debt Refinancing: On May 7, 2026, the company refinanced its debt, entering a new credit agreement with a $25 million term loan and a $10 million revolving facility. This replaced the previous term loan, reducing interest expense.
Guidance, Outlook, and Risks
- Outlook: Management expects seasonality to continue, with higher revenue typically in the fourth quarter. The company is shifting focus toward higher-margin solutions (e.g., DAAP) and subscription-based data services to improve predictability.
- Share Repurchase: A $10 million share repurchase program was authorized in March 2026; however, no shares were repurchased as of June 30, 2026.
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective due to a material weakness regarding data completeness and accuracy from third-party service organizations. Remediation is ongoing.
- Risks: Key risks include customer concentration (top 5 customers represented 47% of 2025 revenue), macroeconomic pressures affecting pharmaceutical marketing spend, and the inability to generate sufficient cash to service debt.
- Subsequent Event: On July 9, 2026, the company repaid approximately $3 million of its New Term Loan.
Investor Verification Checklist
- Customer Concentration: Verify the status of the customer that represented ~10% of 2025 revenue and the uncertainty surrounding future contracts.
- Internal Control Remediation: Monitor progress on remediating the material weakness related to third-party data controls.
- Debt Covenants: Confirm continued compliance with the new Credit Agreement's financial covenants (minimum fixed charge coverage ratio of 1.20:1 and maximum leverage ratio of 2.75:1).
- Revenue Mix: Assess the success of the transition from low-margin managed services to higher-margin subscription and AI-driven solutions.
- Cash Flow Sustainability: Review the ability to service the $19.7 million outstanding term loan balance given the recent revenue decline.